<DOC>
	<DOCNO>NCT01755091</DOCNO>
	<brief_summary>This proof concept study determine safety efficacy dronabinol treatment obstructive sleep apnea syndrome ( OSA ) .</brief_summary>
	<brief_title>Safety Efficacy Study Dronabinol Treat Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Adult 21 64 year age ; 15≤AHI ≤ 50 screen polysomnogram ( PSG ) ESS score ≥ 7 Able understand complete inform consent study assessment form , present Englishspeaking format ; Women childbearing potential ( WCBP ) must negative urine pregnancy test . In addition sexually active WCBP must agree use adequate contraceptive method ( oral , injectable implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) . Arterial oxygen saturation &lt; 75 % &gt; 5 % sleep period time screen PSG ; Occupation life situation may impart risk study participation ( e.g . commercial driver , pilot , police officer , fireman ) ; Motor vehicle accident `` nearmiss '' relate sleepiness ( selfreport ) within 2 year first dose study drug ( Day 8 ) ; Body mass index &gt; 45 kg/m2 Severe obstructive sleep apnea syndrome ( OSAS ) , base clinical judgment Investigator , preclude delay positive airway pressure treatment ; History shift work rotate shift within month prior first dose study drug ( Day 8 ) ; Prior upper airway surgery snore OSAS adult ( ≥ 18 year age ) ; Prior noninvasive treatment OSAS within 6 month prior first dose study drug ( Day 8 ) ; Major surgery within 6 month prior first dose study drug ( Day 8 ) ; Bariatric surgery within 2 year prior first dose study drug ( Day 8 ) . If postbariatric surgery , weight must stable ±5 % ( selfreport ) least 6 month prior first dose study drug ( Day 8 ) . Any form medically manage weight loss program within 6 month prior first dose study drug ( Day 8 ) ; Significant defect nasal patency due anatomical abnormality uncontrolled recurrent episode rhinitis ; Any clinically significant unstable progressive medical condition ; Any primary sleep disorder OSAS determine history , physical examination , Visit 2 PSG ( 7day screen runin period ) ; Clinically significant uncontrolled : chronic obstructive pulmonary disease ( COPD ) , cardiovascular disease , gastrointestinal , respiratory , pancreatic , hepatic , renal , hematologic , endocrine [ include insulindependent diabetes mellitus ( IDDM ) ] , neurological , urogenital , connective tissue , dermatological , thyroid , medical disorder ; Any clinically significant psychiatric disorder ; History seizure disorder ; Treatment prescription antidepressant medication within 1 month prior first dose study drug ( Day 8 ) ; Treatment sedatives , hypnotic psychoactive drug within 30 day prior first dose study drug ( Day 8 ) ; Any complete blood count ( CBC ) liver function test ( LFT ) laboratory value outside normal range , clinical judgment Investigator render subject inappropriate randomization treatment ; Pregnancy [ demonstrate positive urine human chorionic gonadotropin ( hCG ) test ] lactation ; Allergic cannabinoids sesame oil ; History substance abuse ( include alcohol abuse dependence ) laboratory evidence drug abuse Visit 1 drugscreening panel ; Use dietary supplement judgment Investigator may impact sleep breathing behavior ; Average daily caffeine consumption &gt; 500 mg/day ( ~5 cup coffee ) ; Average weekly alcohol consumption &gt; 10 unit ; Unwillingness abstain caffeine alcohol day overnight daytime testing perform ; Participation investigational protocol within 30 day prior first dose study drug ( Day 8 ) ; Any condition , opinion Investigator , place patient unacceptable risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>